The study of modern aspects of determining the costs of self-monitoring of diabetes mellitus
DOI:
https://doi.org/10.24959/sphhcj.22.259Keywords:
retail price; diabetes; costs; self-monitoringAbstract
Aim. To study modern aspects of determining the costs of self-monitoring of diabetes mellitus.
Materials and methods. When conducting the analysis the research objects were recommendations and regulations documents regarding the provision of medical care to diabetes patients (orders of the Ministry of Health of Ukraine, domestic and international clinical guidelines, recommendations of international organizations) and information on retail prices of glucometers and test strips in pharmacies of Kyiv, Lviv, Dnipro and Kharkiv (80 pharmacies) as of 10.01.2022. In the course of the research the content analysis, methods of grouping and summarizing data, mathematical and marketing analysis methods were applied.
Results. Based on the generalization of these international recommendations and legal acts on the provision of medical care to patients with diabetes mellitus, 4 scenarios were identified regarding the number of measurements for self-monitoring. It was determined that foreign manufacturers formed the main range of glucometers for diabetes self-monitoring at the retail pharmaceutical market. The need for self-monitoring of diabetes mellitus per year was determined based on qualitative and quantitative indicators, depending on the type of diabetes mellitus and approaches to pharmacotherapy, taking into account
domestic and international recommendations. It was found that the highest costs for test strips per year were observed for self-monitoring of Type І diabetes (5,986.0-15,622.0 UAH), and insignificant for Type ІІ diabetes with diet therapy (213.2 to 556.4 UAH). In addition, the following costs of self-monitoring (glucometer + test strips) for 1 year were found: for Type І diabetes (insulin therapy) – UAH 6,318.0-15,997.0, for Type ІІ diabetes (insulin therapy) – UAH 4,821.5-12,091.5, Type ІІ diabetes (oral hypoglycemic therapy) – UAH 2,464.0-5,939.0, Type ІІ diabetes (diet therapy) – from UAH 545.2 to UAH 1,165.6.
Conclusions. Based on the analysis conducted, it has been determined that in Ukraine it is appropriate to develop measures to introduce reimbursement of costs for self-monitoring devices, namely glucometers and test strips for all categories of patients. This will help to encourage patients to conduct self-monitoring and, as a result, will become a significant factor in preventing the development of diabetes complications.
Key words: retail price; diabetes; costs; self-monitoring.
References
Bommer, С., Sagalova, V., Heesemann, E., Manne-Goehler, J., Atun, R., Bärnighausen, T., Davies, J., Vollmer, S. (2018). Global Economic Burden of Diabetes in Adults: Projections From 2015 to 2030. Diabetes Care, 41, 963–970. doi: https://doi.org/10.2337/dc17-1962.
Stegbauer, C., Falivena, C., Moreno, A., Hentschel, A., Rosenmöller, M., Heise, T., Szecsenyi, J., Schliess, F. (2020). Costs and its drivers for diabetes mellitus type 2 patients in France and Germany: a systematic review of economic studies. BMC Health Serv Res., 20 (1), 1043. doi: 10.1186/s12913-020-05897-w.
Nemchenko, A. S., Nazarkyna, V. M. (2020). Farmatsevtychnyi zhurnal, 5, 23–33.
Huz, V. S., Zaliska, O. M., Maksymovych, N. M. (2020). Proceeding from Sotsialna farmatsiia: stan, problemy ta perspektyvy : mater. VI mizhnar. nauk.-prakt. internet-konf. (23-24 kvitnia 2020 r.). (pp. 198-200). Kharkiv : NFaU.
Boiko, A. I. (2016). ScienceRise, 3/4, 9-16. doi: 10.15587/2313-8416.2016.64836.
Hermaniuk, T. A., Ivko, T. I., Bobruk, V. P. (2017). Farmatsevtychnyi zhurnal, 1, 37-42.
Volkova, A. V., Kovtun, Ye. Yu. (2021). Sotsialna farmatsiia v okhoroni zdorovia, 7 (1), 3-11. doi: https://doi.org/10.24959/sphhcj.21.212.
Nemchenko, A. S., Titko, I. A., Podgaina, M. V., Korzh, Y. V., Zaytzeva, Y. L. (2018). Legal and organizational economic aspects of the functioning of the main models of health-care systems. Asian Journal of Pharmaceutics, 12 (3), 937-945. doi: https://doi.org/10.22377/ajp.v12i03.2631.
Panfilova, H., Hala, L., Zaytzeva, Yu. L. (2019). Аnalysis of problems and prospects of development of voluntary medical insurance in Ukraine. Journal of Advanced Pharmacy Education and Research, 9 (1), 17-26.
Popovich, L. D., Shestakova, M. V., Potapchik, E. G. et al. (2017). Sakharnyi diabet, 20 (2), 108-118. doi:https://doi.org/10.14341/7077.
EDIC. (1999). Design, implementation, and preliminary results of a long-term follow-up of the diabetes control and complications trial cohort. Diabetes Care, 22, 99-111. doi: 10.2337/diacare.22.1.99.
Kovalov, A., Vereshchak, T., Shtepa, A. (2020). Diabet. Ozhyrinnia. Metabol. Syndrome, 6, 45-62.
Neborachko, M., Pkhakadze, A., Vlasenko, I. (2018). Current trends of digital solutions for diabetes management. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 12 (4), 2997–3003. doi:10.1016/j.dsx.2018.07.014.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
